EFFICACY AND SAFETY OF OPEN-LABEL CAPLACIZUMAB IN PATIENTS WITH EXACERBATIONS OF ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA DURING THE PHASE III HERCULES STUDY

被引：0
|
作者：
Peyvandi, F.
Scully, M.
Cataland, S.
Coppo, P.
Knoebl, P.
Kremer Hovinga, J.
Metjian, A.
de la Rubia, J.
Pavenski, K.
Callewaert, F.
Biswas, D.
De Winter, H.
Zeldin, R. K.
机构：
[1] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Angelo Bianchi Bonomi Hemophilia & Thrombosis Ctr, Milan, Italy
[2] Univ Milan, Milan, Italy
[3] Univ Coll London Hosp NHS Trust, Dept Haematol, London, England
[4] Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA
[5] St Antoine Univ Hosp, Dept Hematol, Paris, France
[6] Vienna Univ Hosp, Div Hematol & Hemostasis, Dept Med 1, Vienna, Austria
[7] Bern Univ Hosp, Univ Clin Hematol, Inselspital, Bern, Switzerland
[8] Bern Univ Hosp, Cent Hematol Lab, Inselspital, Bern, Switzerland
[9] Duke Univ, Sch Med, Div Hematol, Durham, NC USA
[10] Univ Catolica Valencia Hosp Doctor Peset, Hematol Dept, Valencia, Spain
[11] St Michaels Hosp, Dept Lab Med & Pathobiol, Res Inst, Toronto, ON, Canada
[12] Ablynx NV, Clin Dev, Zwijnaarde, Belgium
来源：
HAEMATOLOGICA | 2018年 / 103卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
CO031
引用
收藏
页码：S34 / S34
页数：1
相关论文
共 50 条
  • [31] An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP)
    Shirasugi, Yukari
    Ando, Kiyoshi
    Miyazaki, Koji
    Tomiyama, Yoshiaki
    Iwato, Koji
    Okamoto, Shinichiro
    Kurokawa, Mineo
    Kirito, Keita
    Hashino, Satoshi
    Ninomiya, Haruhiko
    Mori, Shinichiro
    Yonemura, Yuji
    Usuki, Kensuke
    Wei, Helen
    Lizambri, Richard
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 95 (06) : 652 - 659
  • [32] Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab
    Knoebl, P.
    Voelker, L.
    Brinkkoetter, P.
    Kaufeld, J.
    Menne, J.
    Buxhofer-Ausch, V.
    Miesbach, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 84 - 84
  • [33] An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP)
    Yukari Shirasugi
    Kiyoshi Ando
    Koji Miyazaki
    Yoshiaki Tomiyama
    Koji Iwato
    Shinichiro Okamoto
    Mineo Kurokawa
    Keita Kirito
    Satoshi Hashino
    Haruhiko Ninomiya
    Shinichiro Mori
    Yuji Yonemura
    Kensuke Usuki
    Helen Wei
    Richard Lizambri
    International Journal of Hematology, 2012, 95 : 652 - 659
  • [34] Caplacizumab Model-Based Dosing Recommendations in Pediatric Patients With Acquired Thrombotic Thrombocytopenic Purpura
    Bergstrand, Martin
    Hansson, Emma
    Delaey, Bernard
    Callewaert, Filip
    Sousa, Rui De Passos
    Sargentini-Maier, Maria Laura
    JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (03): : 409 - 421
  • [35] Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy
    Miyakawa, Yoshitaka
    Imada, Kazunori
    Ichinohe, Tatsuo
    Nishio, Kenji
    Abe, Takayuki
    Murata, Mitsuru
    Ueda, Yasunori
    Fujimura, Yoshihiro
    Matsumoto, Masanori
    Okamoto, Shinichiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 104 (02) : 228 - 235
  • [36] Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy
    Yoshitaka Miyakawa
    Kazunori Imada
    Tatsuo Ichinohe
    Kenji Nishio
    Takayuki Abe
    Mitsuru Murata
    Yasunori Ueda
    Yoshihiro Fujimura
    Masanori Matsumoto
    Shinichiro Okamoto
    International Journal of Hematology, 2016, 104 : 228 - 235
  • [37] Safety and efficacy of caplacizumab retreatment in a real-life monocentric cohort of patients with immune-mediated thrombotic thrombocytopenic purpura
    Caocci, G.
    Mulas, O.
    Mantovani, D.
    Bandinu, N.
    La Nasa, G.
    THROMBOSIS RESEARCH, 2023, 228 : 189 - 190
  • [38] Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 Study
    Naing, Aung
    Mahipal, Amit
    Javle, Milind
    Wang, Judy
    Bauer, Todd M.
    Bajor, David L.
    Elias, Anthony D.
    Shields, Anthony
    Davis, Elizabeth
    Chawla, Sant
    Safran, Howard
    Powderly, John D.
    D'Amato, Gina
    Meyer, Christian F.
    Tang, Xiongwen
    Yao, Sheng
    Keegan, Patricia
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2025, 8 (01) : 71 - 81
  • [39] Effectiveness and safety of caplacizumab in acquired thrombotic thrombocytopenic purpura: health technology assessment and classification according to the methodology established in Colombia
    Soto-Mora, Jahir A.
    Gomez-Espitia, Lina M.
    Lasalvia, Pieralessandro
    Moreno, Camilo A. Castellanos A.
    Vanegas, Carol A. Casallas A.
    Gutierrez, Sergio A. Londono A.
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2023, 39 (01)
  • [40] ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA IN HIV POSITIVE PATIENTS SUCCESSFULLY TREATED WITH CAPLACIZUMAB: ABOUT TWO CASES.
    Baes, Dulciane
    Nicolazzi, Paul
    Moulonguet, Florence
    Simphal, Philippine
    Hazzan, Marc
    Maanaoui, Mehdi
    Provot, Francois
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2020, 35 : 545 - 545
12345